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Abstract 
Thoracic aortic aneurysm (TAA) disease affects about 15,000 people each 
year.4  However, the cellular mechanism of TAA disease is not known,5 resulting in there being a 
high demand for research on the condition. The Akerman and Ikonomidis laboratory has 
demonstrated matrix metalloproteinases (MMPs) to be large players in the disease mechanism.12 
As furin has been found to modulate MMP levels, this protein subsequently plays a role in TAA 
progression.14 However, an effective means for localized transfection of vectors for these proteins 
into tissues has not been established.8,9 I hypothesize that we can overexpress furin in the murine 
thoracic aorta through electroporation. An overexpression vector for furin was generated and 
confirmed by transforming the vector into E. coli, purifying the double-stranded DNA (dsDNA) 
and running it on an ethidium bromide gel, followed by final confirmation via sequencing. Direct 
electroporation of the murine thoracic aorta was performed. Electrical conditions comprised of 8 
square-wave pulses for 10 ms each, at 200 V. These data provide significant steps towards TAA 
research, as there is currently very little understanding of the molecular mechanism behind TAA 
development;5 by contributing to this research, we are one step closer to defining a noninvasive 
treatment for the disease. 
Introduction 
The aorta is the biggest artery in the body, beginning in the left ventricle and descending 
into the lower abdomen. It is the body’s main artery, functioning to propel blood systemically.10 
Due to its large anatomical significance, one can imagine the disastrous effects of this vessel 
going awry. The overall  motivator for my research is the lack of a noninvasive treatment option 
for thoracic aortic aneurysm (TAA) disease.2 About 15,000 people are affected by TAA disease 
in the United States annually,4 but there is no way to treat the disease without performing 
surgery.2 The cost of the current treatment option--surgical intervention--is disproportionately 
high, highlighting the importance for more treatment options to be devised. Further, patients with 
TAAs are generally asymptomatic until the aorta ruptures or dissects; therefore there are likely 
many more individuals suffering from TAAs than we know of.1 
A thoracic aortic aneurysm (TAA) is defined as a dilation of the supradiaphragmatic 
aorta by 50%.2 During TAA disease the extracellular matrix breaks down, causing the thoracic 
aorta to become stiff and lose compliance, as the elastin and collagen within the extracellular 
matrix are degraded.2 Dilation of the thoracic aorta accompanies this breakdown of the 
extracellular matrix. In non-diseased vessels, collagen and elastin do not degrade in a short 
period of time. However, these proteins can be specifically broken down by matrix 
metalloproteinases (MMP).2 Matrix metalloproteinases are proteolytic enzymes, which are 
divided into different classes based upon what cellular component they degrade.3 As the 
degradation of the extracellular matrix seems to be especially important in the progression of 
TAA, a link may be made between this degradation and the metalloproteinases which assist in 
this extracellular breakdown.  
Of the matrix metalloproteinases, Specifically focused on in my research is membrane 
type-1 matrix metalloproteinase (MT1-MMP). Previous research has shown it to play a direct 
role in extracellular degradation and subsequent TAA development.11,12 Membrane type-1 matrix 
metalloproteinase can activate other MMPs as well as cellular signaling pathways.7 This is 
important for aneurysm development, as this activation of metalloproteinases may result in 
degradation of the extracellular matrix, as seen in aneurysm disease.2 Additionally, MT1-MMP 
has the ability to release cytokines and growth factors, which can exacerbate the dilation of the 
vessel that occurs in aneurysms, making this metalloproteinase especially significant to the 
development of TAAs.12  For instance, MT1-MMP has been demonstrated to release sequestered 
TGF-β from the extracellular matrix.12 Interestingly, multiple other laboratories have defined a 
direct role for TGF-β in aneurysm development.13 As TGF-β is dysregulated in aneurysms and 
MT1-MMP is expressed in larger quantities in thoracic aortic aneurysms, this suggests that MT1-
MMP plays a role in the disease, altering cell-signaling and growth pathways.12 
While MT1-MMP certainly plays a role in TAA development, the mechanism by which it 
does so is still unknown.5 In order to continue our research on the cellular mechanism of the 
disease, we must have a way to effectively manipulate the amount of MT1-MMP in the cells and 
aorta. Furin is a cellular endoprotease which activates many proprotein substrates, including 
MT1-MMP.14 My lab has recently focused on studying furin as an upstream regulator of MT1-
MMP. By studying levels of furin in cells and tissues, we can indirectly determine the amount of 
active MT1-MMP and thus study its effect on aneurysm development. An efficient way to 
locally manipulate the amount of protein in cells and tissues has yet to be discovered for the 
aorta. Although lipid-based transfection and transduction can transfer genetic material into cells, 
this is an inefficient method, having very low rates of success.8,9 Additionally, these methods do 
not provide localized gene transfer in tissues, but are rather systemic, affecting other parts of the 
body besides the diseased tissue.8 My lab wants to specifically target the thoracic aorta to 
modulate gene expression in. This sort of targeted expression has yet to be discovered.  
Fibroblasts play a large role in maintaining vascular homeostasis.15 They also have the 
ability to differentiate into myofibroblasts. In pathological conditions, fibroblasts have been 
demonstrated to take on such different phenotypes.16 When they change it is possible that 
vascular homeostasis may subsequently change. This leads our lab to focus on fibroblast cells in 
our studies of thoracic aortic aneurysm development. In order to study the initiation and 
progression of TAA, this laboratory has developed a murine model, in which calcium chloride is 
used to induce thoracic aortic aneurysms. This murine model has been demonstrated to 
recapitulate hallmarks of the clinical pathologies of the disease.12 Previously, our lab induced 
TAAs in mice which were heterozygously deficient in MT1-MMP and found that with this 
deficiency, the mice did not develop aneurysms as contrasted to control mice, thereby proving 
the critical role in which MT1-MMP plays in aneurysm development. Our current model, 
however, makes use of wildtype mice to study the mechanisms of TAA, taking into account the 
importance that MT1-MMP holds for disease progression. By conducting research to determine 
an optimal method for gene insertion into aortic tissue, we take one step closer towards 
developing a therapeutic strategy for the attenuation of the disease.  
To recap, especially of concern to our research is the development and progression of 
TAA disease as well as what biomolecular and cellular processes are associated with the disease. 
The obvious connection between furin, MT1-MMP, and TAA disease alongside the lack of 
noninvasive treatment options2 for the disease highlights the need for further study on the matter. 
My research focuses on developing an effective method for inserting furin vectors into aortic 
fibroblasts and murine aortas. By determining an efficient and reliable method of gene insertion, 
we can further study how higher protein expression of furin changes TAA development. I 
hypothesize that we can overexpress furin in the murine thoracic aorta through electroporation.  
Methods 
Generation of overexpression vectors 
Overexpression vectors for MT1-MMP and furin were obtained. These vectors were 
transformed into NEB 5-alpha Competent E. coli using the following procedures. Each vector 
tube was centrifuged and placed on ice. The E. coli cells were thawed on ice and aliquoted into 2 
tubes of 50 μL each. One μL of the overexpression vector was pipetted into each 50 μL solution 
of the E. coli cells and each solution was mixed by tapping gently. The sample was incubated on 
ice for 30 min. Following this incubation, the sample was heat shocked in a 42 °C water bath for 
30 s. Samples were then removed from the bath and placed on ice for 2 min. Following this, 250 
μL of pre-warmed S.O.C. medium was added to the sample and the sample was shaken at 225 
rpm for 1 hr at 37 °C. Kanamycin agar plates were made up at a concentration of 25 μg/mL. 
Three plates were streaked with the sample mixture with the following volumes: 20 μL, 110 μL, 
200 μL. Plates were inverted and incubated at 37 °C overnight. The following day, 6 colonies 
were selected from each plate. They were then grown up overnight in 5 mL of an LB broth and 
kanamycin solution (concentration of 50 μg/mL). Each tube was then shaken overnight at 225 
rpm at 37 °C. The resulting bacteria was purified to elute dsDNA using the QIAprep® Plasmid 
Giga Kit (cat. no. 12191).  
Confirmation of vectors 
Confirmation of the vectors was obtained through a restriction digest. Restriction 
enzymes MluI and AsiSI were used for the digestion of MT1-MMP and furin vectors. The 
samples were digested in a thermocycler using the following protocol: 37 °C for 1 hr, 80 °C for 
20 min, and finally 4 °C until ready to load into an agarose gel. Digested samples were loaded 
into a 1% agarose gel containing ethidium bromide, which allows for visualization of DNA 
under UV light. Gel electrophoresis was performed at 90 V for 60 min using 1x TAE buffer. The 
furin vector was sent off for chain-terminating sequencing. Once the sequence came back, it was 
inputted into BLAST for final confirmation of the vector. 
Murine anesthetic induction and maintenance 
Prior to being anesthetized, each mouse was weighed. Directly after, each mouse was 
initially anesthetized by being placed in a customized induction chamber. The induction chamber 
was constructed of 2 containers stacked on top of each other, with 4x4 gauze being placed in the 
bottom container. Liquid phase isoflurane--a general anesthetic--was placed onto the gauze, 
which then vaporized and rose into the top container. Each mouse was placed in the top 
container so that direct contact with liquid phase isoflurane was avoided, but rather, anesthetic 
effect was achieved through the inspiration of the vaporized isoflurane. The chamber was 
constructed in a way which ensured administration of 3-4% isoflurane vapors in room 
temperature air. Determination of anesthetic depth was conducted through examination of 
whisker movement, eyelid reflexes, and toe pinch reflexes. The cessation of whisker movement 
and absence of each reflex indicated that the mouse was asleep. Following the placement of the 
mouse into the induction chamber, each mouse was moved out of the induction chamber and 
onto the sterile field. Mice were placed in a supine position and, from this point forward, 
isoflurane was delivered to the murine through a nose cone. Anesthesia was regulated to ensure 
the continued absence of whisker movement and reflexes as previously described. Prior to the 
surgical procedure, 100 μL of 0.03 mg/mL buprenorphine was also injected into mice for pain 
management.17   
Murine thoracotomy 
The descending aorta was accessed by thoracotomy. In preparation for the thoracotomy, 
fur in the thoracic area was depilated. Immediately after, the skin on the surgical site was 
prepped. The skin was wiped with betadine and then 70% EtOH. This was repeated 3 times. 
Veterinary eye ointment was also applied to each eye to prevent dryness. An incision was made 
in between the 4th and 5th ribs. All muscles overlying the intercostal space was dissected free 
and retracted with 5.0 silk threads. Only intercostals were transected.17  
Electroporation of murine aorta 
Following the murine thoracotomy, the adventitial surface of the aorta was exposed. The 
artery was then soaked by a solution composed of 10 μL sterile PBS and 90 μL of the vector of 
interest. Two 3 mm gold plates were then positioned on either side of the thoracic aorta. The 
BTX-ECM 830 in vivo square wave electroporation system, Harvard Apparatus was then used to 
administer 8 electrical pulses. The pulses delivered were each 10 ms in duration and were 200 V 
in magnitude. Postoperative pain management was carried out through the administration of 
buprenorphine every 8-12 hours for the first 48 hours after surgery.17 All animal procedures were 
approved by the UNC Institutional Animal Care and Use Committee.  
Harvest surgery 
Two days following the electroporation procedure, the thoracic aorta was extracted using 
the thoracotomy methods as described above.  
Homogenization  
Following obtainment of the thoracic aorta, the artery was combined with a PBS + 
inhibitor cocktail and homogenized using a glass homogenizer.  
BCA and Western Blotting 
After the thoracic aorta was homogenized, a BCA was completed to determine protein 
concentration and a western blot was performed using standard procedures. Ten μg of total 
protein was loaded onto the gel. The western blot was then analyzed to determine relative protein 
concentration of furin. Protein concentrations were normalized against GAPDH concentrations 
from the tissue. 
Electroporation of aortic fibroblast cells 
Healthy and normal aortic fibroblast cells were grown up in culture using standard cell 
culture procedures. Fibroblast growth media was used, which contained the growth media, 10 
mL of SupplementMix fibroblast growth supplement (cat. no. 395325), 50 mL fetal bovine 
serum, and 25 μL gentamicin per 500 mL. Upon becoming confluent, cells were lifted and 
centrifuged at 500 x g for 4 min. Supernatant was discarded and the pellet was resuspended with 
an electroporation buffer to a concentration of 4000 cells/μL. One of two electroporation buffers 
was used. The first consisted of 10 mM Tris HCl (pH 7.5), 270 mM sucrose, and 1mM MgCl2. 
The second consisted of 10mM Tris (pH 8.0), 1mM EDTA, and 140 mM NaCl.  
The vector was pipetted into the solution to bring the total vector concentration to either 
0.25 μg/150k cells, 0.5 μg/150k cells, or 1.0 μg/150k cells. A cuvette was chilled on ice and the 
cell solution was pipetted into the cuvette. Cells were electroporated using one pulse of either 
250 V, 350 V, or 450 V. Pulses lasted for 10 ms and a square wave shape was used. The gap 
between electrodes was 4mm for all conditions. The concentration and voltage used in 
electroporation was dependent on the electrical conditions being tested for a certain trial. 
Results 
Vector confirmation 
Vectors were made to overexpress furin. The furin overexpression vector was confirmed 
through a restriction digest. Figure 1 shows a vector map, describing the composition of the furin 
overexpression vector. A restriction digest was performed to verify the composition of the 
vector. Figure 2 shows the restriction digest for the furin overexpression vector. Because the 
length of each band on the restriction digest coincides with the composition of the furin 
overexpression vector, as represented by figure 1, this provides confirmation of the vector.  
 
Following the confirmation of the vector by restriction digest, the vector was sent out for 
sequencing. Chain-terminating sequencing was used to provide the complete nucleotide 
sequence for the furin vector. After inputting the sequence into BLAST, the sequence of the 
vector was matched with known sequences for the furin ORF and Myc-DDK tag. An Myc-DDK 
tag is merely a sequence added onto the vector which codes for a specific protein. Expression of 
the Myc-DDK protein can then be used as an indicator of the vector’s presence. We used the 
Myc-DDK tag to confirm the presence of furin in downstream applications of our research. The 
Myc-DDK tag sequence was confirmed as being a part of our vector sequence, as shown as a 
band on the restriction digest and in our BLAST results. Figure 3 shows the blast results for the 
furin vector sequence.  
 
Vector production and purification 
Following the confirmation of the vector, I produced large amounts of the vector by 
transduction into E. coli and dsDNA purification. The QIAprep® Plasmid Giga Kit (cat. no. 
12191) was used to grow up bacteria and purify large amounts of the vector. A nanodrop 
spectrophotometer was used to determine the final vector concentration and purity. The purity of 
the final vector sample measured between 1.8 and 2, measured by an optical density of A260/280. 
Protein quantification 
Following the electroporation of the furin vector into mice, thoracic aortic tissue was 
homogenized and collected for protein. A BCA was run to determine the concentration of total 
protein. Concentrations obtained from the BCA were then used to calculate and load 10 μg of 
total protein into a western blot. The concentration of Myc-DDK protein present in the murine 
thoracic aorta as compared to control GAPDH was then analyzed. Figure 4 shows an image of 
the western blot. Figure 5 shows a graph which quantifies protein concentration. After analyzing 
protein concentrations, there was determined to be a 3-fold increase in furin expression from a 
murine thoracic aorta which was electroporated, as compared to the control.  
 
Discussion 
         As previously discussed, MT1-MMP has been shown to be a large player in thoracic 
aortic aneurysm development. Furin is an upstream regulator of MT1-MMP, so manipulating it 
and studying the downstream effects would be valuable for further understanding the disease 
mechanism of TAA disease. However, as there is no efficient way of locally transfecting furin 
vectors into thoracic aortic tissue, I hope to provide a reliable method for doing so. The aim of 
my study was to prove electroporation as being an effective method for transfecting vectors into 
murine thoracic aortic tissue. As high concentrations of Myc-DDK tag proteins were shown to be 
present in experimental murine thoracic aortic tissue, as compared to control tissues, this shows 
that electroporation provides a successful method for gene transfer in aortic tissue. Because the 
concentrations of Myc-DDK proteins coincide with those of furin, my data shows the successful 
transfection of a furin overexpression vector by means of electroporation. This proves 
electroporation to be a promising method for localized gene transfer in the thoracic aorta, 
supporting my hypothesis that we can overexpress furin in the murine thoracic aorta through 
electroporation.  
Upon growing up and purifying large quantities of the vector, a restriction digest was 
performed to confirm the vector’s presence. The 2 bands which resulted from the restriction 
digest were 2379 and 4900 bp. As the ORF for furin is 2379 bp, this confirms the presence of 
furin in the vector. Additionally, the size of the remaining band coincides with the expected size, 
as determined through the vector map. The total vector should measure to be about 7300 bp, and 
since both bands add up to equal this amount, this confirms the presence of the vector in our 
dsDNA. Furthermore, the consistent pairing-up of nucleotides between the searched and known 
sequences for furin in BLAST further confirms the vector.  
Following mass production of the vector, final concentration was determined through a 
nanodrop spectrophotometer. In addition to obtaining the vector concentration to be used in 
downstream applications, the nanodrop provided us with a number indicating the dsDNA purity. 
Because our purity value was in between 1.8 and 2, this indicates an acceptable value, ensuring 
that the dsDNA was not contaminated with extraneous elements. 
As previously discussed, following the electroporation of murine thoracic aortic tissue, 
the tissue sample was taken and homogenized for protein collection. These protein samples were 
loaded and run in the western blot, as displayed by  figure 4. The presence of an 87 kDa band 
indicates that furin protein is being expressed. Additionally, due to the difference in brightness of 
furin and Myc-DDK bands in the electroporated sample, versus the control, protein 
concentrations were quantified. Figure 5 shows this quantification. The 3-fold increase in 
concentration of furin in the electroporated sample, as compared to the control proves 
electroporation to be an effective method for localized transfection in the thoracic aorta.  
After showing successful electroporation in murine thoracic aortic tissue, electroporation 
was taken a step further and performed on the cellular level. Following the electroporation of 
furin vectors into murine thoracic aortas, we have begun repeating the process with MT1-MMP 
vectors. Optimization of electroporation should be similar between furin and MT1-MMP due to 
their similar sizes. We have constructed a MT1-MMP overexpression vector to include a GFP 
tag, allowing us to rapidly visualize successful transfection of the vector. The MT1-MMP 
vectors were confirmed using the same process as completed with furin.  
Following the creation and confirmation of the MT1-MMP overexpression vector, these 
vectors were transmitted into aortic fibroblast cells using electroporation. We have since begun 
optimizing the electrical conditions for electroporation. Several trials of electroporation will be 
performed to determine the overall optimal electrical conditions for administering vectors into 
aortic fibroblast cells. The optimal electrical conditions are those conditions which result in the 
highest percentage of vetor being expressed in the aortic fibroblast cells. Because the MT1-MMP 
vector not only overexpressed MT1-MMP, but also included a GFP tag, the presence of MT1-
MMP could be visualized under a microscope, as its abundance is represented by bright green 
fluorescence. This allows the percent expression of the MT1-MMP vector to be determined via 
fluorescent microscopy. Several variables can be altered which affect the efficiency of 
electroporation: (1) voltage, (2) type of electroporation buffer used, (3) distance between the 
electrodes, (4) duration of electrical pulse, (5) number of electrical pulses administered, and (6) 
concentration of vector used. Trials will be performed in the order stated above to determine the 
optimal electrical condition.  
We expect to generate parabolic curves for each variable, holding the voltage constant 
after the optimal voltage is determined in the first trial. The peak of each curve indicates the 
optimal level for each variable tested. Ultimately, values for each of the 6 variables previously 
stated will be obtained, allowing us to determine an efficient method for electroporating vectors 
into aortic fibroblast cells.  
Electroporation is favorable as contrasted to other transfection methods due to its ability 
for localized transfection as compared to systemic gene transfer. Findings from previous research 
indicate difficulty in transfecting at high efficiency using other means of gene transfer (e.g. lipid-
based transfection, transduction). While transduction performed through viral vectors provides a 
very efficient means of gene transfer, this method is systemic.8 The inability to localize gene 
transfer to a particular tissue results in the method being difficult to apply therapeutically. 
Introducing a vector directly into a tissue of interest may be favorable over the widespread nature 
of transduction. Why introduce a treatment systemically for a condition which is localized to an 
individual tissue?  
While lipid-based transfection provides a means for localized gene transfer, its efficiency 
is low in primary cells.9 The high efficiency exhibited by my results proves electroporation to be 
a promising method of gene transfer. Additionally, as electroporation has never been completed 
in the thoracic aorta, my findings are novel in that they prove the method to be applicable to this 
tissue.  
Even such, our methods of electroporation do pose their own limitations. Following 
electroporation, it is not known how long vector expression will last. Our lab’s murine model of 
thoracic aneurysm development requires 4 weeks to pass in order for TAA disease to develop. If 
electroporated vectors do not remain in the target tissue for over this amount of time, this 
presents a challenge for studying the disease attenuation. Additionally, as previously mentioned, 
the optimal electrical conditions for electroporation must still be discovered. There may be other 
off-target effects of electroporating furin into tissue, however, more research must be conducted 
to specifically identify these caveats. While we know that electroporation is an efficient method 
of gene delivery, we must determine optimal values for several variables, each of which 
independently change electroporation efficiency.  
Our research holds great significance with regards to thoracic aortic aneurysm disease. 
Not only do our findings fit into the greater research about furin and MT1-MMP, but they 
provide a greater insight as to methods for localized gene transfer. Currently, not much is 
understood about the molecular mechanisms of thoracic aortic aneurysm disease. Because our 
results provide evidence for a more efficient method of vector transfection, these methods can be 
applied towards other research to further understand the mechanisms behind TAA disease, thus 
ultimately working towards a reliable treatment method for TAA disease.  
Approximately 15,000 people in the United States are affected by TAA.4 Although this 
number, at first, seems small, this value is likely underestimated as aneurysms often go 
undiagnosed due to them being characteristically asymptomatic until they become life-
threatening. When a patient is diagnosed with thoracic aortic aneurysm disease, the only 
treatment options involve surgery and monitoring the aneurysm to determine if its size puts a 
patient at risk for rupture. Additionally, when one requires a surgical procedure for a TAA, he or 
she undergoes the risks which come with surgery. Furthermore, these treatments do not address 
the underlying workings of the disease, but rather, attempt to prevent the aneurysm from 
rupturing, which leads to rapid hemorrhaging and a subsequent high risk of fatality.  Our 
research, however, provides a step towards the development of a thorough understanding of the 
molecular and cellular characteristics associated with TAA, which could potentially provide a 
new therapeutic strategy towards disease attenuation.  
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